Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results
Outcome from End-of-Phase 2 Meeting Supportive of a Placebo-Controlled Phase 3 Trial Updated 12 and 24-Month Data from Phase 2 […]
Cemtrex Reports Second Quarter 2024 Financial Results
Hauppauge, NY, May 14, 2024 (GLOBE NEWSWIRE) — – Cemtrex Inc. (NASDAQ: CETX, CETXP), an advanced security technology and industrial services […]
NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer
PARIS and CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) — NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a […]
Stryve Foods, Inc. Reports Fiscal 2024 First Quarter Results
Retail Sales Velocity Increasing +23.2% Year-over-Year1Improved Adj. EBITDA Loss by 35.2% Year-over-Year3Reiterating Net Sales Guidance Range of $24M to $30M […]
AMD Announces Upcoming Events for the Financial Community
SANTA CLARA, Calif., May 14, 2024 (GLOBE NEWSWIRE) — Today, AMD (NASDAQ: AMD) announced the following events for the financial […]
Blink Charging Selected as an Official Electric Vehicle Charger and Network Services Provider for State of New York
Blink chosen as one of the EV charging providers designated to provide expanded charging infrastructure and support a more sustainable […]
CooperCompanies to Participate in the William Blair Growth Stock Conference
SAN RAMON, Calif., May 14, 2024 (GLOBE NEWSWIRE) — CooperCompanies (Nasdaq: COO), a leading global medical device company, will participate […]
Zapata AI Partners with Tech Mahindra to Transform Network and Customer Operations Through Industrial Generative AI for Global Telecom Customers
BOSTON, May 14, 2024 (GLOBE NEWSWIRE) — Zapata Computing Holdings Inc. (“Zapata AI” or the “Company”) (Nasdaq: ZPTA), the Industrial […]
Firsthand Technology Value Fund Announces First Quarter Financial Results, NAV of $0.02 Per Share
SAN JOSE, Calif., May 14, 2024 (GLOBE NEWSWIRE) — Firsthand Technology Value Fund, Inc. (OTCQB: SVVC) (the “Fund”), a publicly […]
Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
Vincerx continued to progress Phase 1 dose-escalation studies for VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC), and VIP236, a […]
